By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


FibroGen, Inc. 

225 Gateway Boulevard

South San Francisco  California  94080  U.S.A.
Phone: 650-866-7200 Fax: 650-866-7202



Company News
Astellas (ALPMY) And FibroGen (FGEN) Announce First Patient Treated In Phase III Studies And Positive Phase II Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan 7/26/2016 8:17:58 AM
FibroGen (FGEN) Gets $62 Million License Payment from Partner AstraZeneca PLC (AZN) 7/8/2016 6:41:08 AM
FibroGen, Inc. (FGEN) Release: Promising Phase II Data Show Roxadustat Corrected Anemia In Chronic Kidney Disease Patients Before Intervention With Dialysis 4/21/2016 8:25:15 AM
FibroGen, Inc. (FGEN) Announces Fiscal 2015 Financial Results 3/1/2016 8:32:47 AM
FibroGen, Inc. (FGEN) Publishes Encouraging Phase II Anemia Data Demonstrating Roxadustat’s Ability To Maintain Hemoglobin Levels In Patients With Chronic Kidney Disease 2/16/2016 10:46:46 AM
FibroGen, Inc. (FGEN) Appoints Jeffrey Edwards To Board Of Directors 10/30/2015 9:48:41 AM
FibroGen, Inc. (FGEN) Release: Phase II Data For Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Show Anemia Correction In Incident Dialysis Chronic Kidney Disease Patients Regardless Of Iron Repletion Status, Iron Supplementation Regimen, Or Dialysis Modality 10/23/2015 11:15:26 AM
FibroGen, Inc. (FGEN) Announces Second Quarter 2015 Financial Results 8/14/2015 9:54:18 AM
FibroGen, Inc. (FGEN) Release: Nephrology Dialysis Transplantation Reports Phase II Data Of Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Shows Improved Hemoglobin Levels In Non-Dialysis CKD Subjects With Anemia 8/13/2015 7:43:47 AM
FibroGen, Inc. (FGEN) To Report Second Quarter 2015 Financial Results On August 13, 2015 8/10/2015 10:20:58 AM